| 46.24 -0.27 (-0.58%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 55.16 | 1-year : | 64.43 |
| Resists | First : | 47.22 | Second : | 55.16 |
| Pivot price | 43.27 |
|||
| Supports | First : | 43.16 | Second : | 40.65 |
| MAs | MA(5) : | 45.97 |
MA(20) : | 43.42 |
| MA(100) : | 40.16 |
MA(250) : | 0 | |
| MACD | MACD : | 1 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 88.1 |
D(3) : | 91.2 |
| RSI | RSI(14): 67.7 |
|||
| 52-week | High : | 49.61 | Low : | 31.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EXEL ] has closed below upper band by 14.9%. Bollinger Bands are 65.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 46.99 - 47.24 | 47.24 - 47.46 |
| Low: | 45.33 - 45.66 | 45.66 - 45.92 |
| Close: | 45.75 - 46.25 | 46.25 - 46.65 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Mon, 15 Dec 2025
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Thu, 04 Dec 2025
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? - Yahoo Finance
Wed, 03 Dec 2025
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
Tue, 04 Nov 2025
Exelixis Inc (EXEL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Tue, 04 Nov 2025
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
Tue, 28 Oct 2025
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 268 (M) |
| Shares Float | 228 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 97.5 (%) |
| Shares Short | 21,360 (K) |
| Shares Short P.Month | 19,790 (K) |
| EPS | 2.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.06 |
| Profit Margin | 29.6 % |
| Operating Margin | 42.8 % |
| Return on Assets (ttm) | 17.7 % |
| Return on Equity (ttm) | 30.5 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 8.24 |
| Sales Per Share | 8.54 |
| EBITDA (p.s.) | 3.17 |
| Qtrly Earnings Growth | 72.5 % |
| Operating Cash Flow | 791 (M) |
| Levered Free Cash Flow | 541 (M) |
| PE Ratio | 19.42 |
| PEG Ratio | 0 |
| Price to Book value | 5.73 |
| Price to Sales | 5.41 |
| Price to Cash Flow | 15.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|